UCART-22 is a gene-modified cell therapy commercialized by Cellectis, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of UCART-22’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Net Present Value Model: Cellectis SA's UCART-22

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for UCART-22 is expected to reach an annual total of $27 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

UCART-22 Overview

UCART-22 is under development for the treatment of relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma (B-NHL). The drug candidate is an allogeneic gene-edited T-cell product candidate. It is an immunotherapy comprising of CAR T cells and acts by targeting CD22. It was also under development for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It is administered through intravenous route.

Cellectis Overview

Cellectis, operates as a clinical-stage biopharmaceutical company. It carries out research, develop and commercialize gene editing technology. The company’s pipeline products include UCART22, UCART123, UCART20x22, ALLO-501A 1, ALLO-715 3, ALLO-605 3, ALLO-316 4. z Its pipeline candidates treat Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma, Multiple Myeloma, Renal Cell Carcinoma. Cellectis’s pioneer, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It works in partnership with Allogene Therapeutics, Servier, Iovance Biotherapeutics, Inc, Cytovia Therapeutics, Inc., It operates in New York and Paris. Cellectis is headquartered in Paris, France.
The company reported revenues of (US Dollars) US$9.2 million for the fiscal year ended December 2023 (FY2023), a decrease of 64.3% over FY2022. The operating loss of the company was US$97.3 million in FY2023, compared to an operating loss of US$89.7 million in FY2022. The net loss of the company was US$101.1 million in FY2023, compared to a net loss of US$106.1 million in FY2022.

For a complete picture of UCART-22’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.